Abstract 1649P
Background
Precision medicine for pancreatic cancer (PC) is one of the promising treatment strategies. However, only a few patients can receive genotype-matched treatments for the low detection rate of actionable genomic alterations, therefore the clinical utility of comprehensive genomic profiling (CGP) is still unknown. On the other hand, CGP gives us a lot of information such as prognosis, future eligibility for genotype-matched clinical trials, and it may affect physician’s treatment strategies. The present study was to investigate the contribution to prognosis of CGP, and its appropriate timing in the treatment of advanced PC.
Methods
This was a single-center, retrospective cohort study. Patients who were diagnosed as recurrent or metastatic PC with adenocarcinoma or adenosquamous carcinoma and underwent systemic chemotherapy between April 2018 and March 2022 were recruited. We reviewed the medical records and collected data of patient characteristics, survivals, and genomic information. We compared overall survival (OS) according to those who had received CGP (CGP group) or not (non-CGP group), and those who had performed CGP before or after initial chemotherapy.
Results
A total of 107 patients were eligible, in which 47 patients had received CGP. Patient characteristics were not statistically different between two groups except for age. OS was significantly longer in CGP group than non-CGP group (median, 29.7 vs 13.4 months; hazard ratio [HR], 0.51; 95% confidence interval [CI], 0.30–0.89; P < 0.017). OS tended to be longer in patients who had received CGP before the initiation of systemic chemotherapy than those who had received CGP after initial chemotherapy (median, 40.1 vs 24.0 months; HR, 0.29; 95% CI, 0.085–1.02; P=0.054). Actionable genomic alterations were detected in 16 patients (34.0%), whereas genotype-matched treatments were implemented for five patients (10.6%).
Conclusions
In the present study, OS was prolonged in patients who had undergone CGP irrespective of implementation of genotype-matched treatments, suggesting that CGP could help physicians to select the optimal treatment strategies for advanced PC in clinical practice. Given the extremely poor prognosis of the disease, earlier timing of CGP is considered.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1624P - Predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216)
Presenter: Manfred Lutz
Session: Poster session 22
1626P - A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer
Presenter: Anna Varghese
Session: Poster session 22
1629P - Modified-FOLFIRINOX-losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase II study
Presenter: Alshaimaa Alhanafy
Session: Poster session 22
1630P - Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers
Presenter: Ashwini Cheryl Kanhailal
Session: Poster session 22
1631P - Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC)
Presenter: Gabriela Fuentes
Session: Poster session 22
1632P - Organoids as tools for functional precision oncology in advanced pancreatic cancer
Presenter: Alice Boileve
Session: Poster session 22
1633P - Development and clinical validation of news transcriptomic tools for predicting the response to individual drug of the mfolfirinox regimen in patients with pancreatic ductal adenocarcinoma
Presenter: Nicolas Fraunhoffer
Session: Poster session 22